Michelle Xia

Michelle Xia

Michelle Xia (#2929)

Global Rank #2929
Country Rank #887
Country United States

We focus on science and biology and the most advanced technology. I think that makes the difference.

  • $ 1 B
  • Biotech
  • United States
  • F
  • 59 Years

Snapshot

Quick Facts

Global Rank #2,929
Country Rank #887
Net Worth $1.3B
Previous Worth $1.3B
Worth Change +$0.0B
Country United States
Industry Biotech
Age 59 Years
Gender F
Worth As Of May 4, 2026
Residence Zhongshan, China
Citizenship United States

Profile Data

Personal Stats

Age 59
Source Of Wealth Biotech, Self Made
Residence Zhongshan, China
Citizenship United States
Education Ph.D, Newcastle University; Bachelor of Science, Sun Yat-sen University
Net Worth Change +$0.0B +0.0% from previous worth
Previous Net Worth $1.3B
Current Net Worth $1.3B

Worth as of May 4, 2026

About Me

Michelle Yu Xia is cofounder, chairwoman and CEO of China-based biotech firm Akeso, which has multiple approved drugs in China to treat cancer. Akeso has captured attention in the biotech world because one of its drugs outperformed Merck's bestseller Keytruda in a head to head Phase 3 trial in 2024. The success of that Akeso drug, ivonescimab, drove up the price of Akeso's shares; the company is listed on the Hong Kong Stock Exchange. Prior to Akeso, Xia worked in research and at U.S. biotech firms for a dozen years starting in the mid 1990s and obtained U.S. citizenship while in America. Akeso licensed its most promising cancer drug to Miami-based firm Summit Therapeutics in 2022 for markets including the U.S., Europe and Japan.

Achievements

Forbes List Highlights

A snapshot of the list placements and rankings connected to Michelle Xia.

#3185
Billionaires (2026)

Wealth Growth

Net Worth Growth Over Time

Tracking Michelle Xia's net worth journey over the years, highlighting key growth phases and financial milestones.